查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048262

人類肝臟模型市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Human Liver Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (2D Models, 3D Bio Printing, Liver Organoids), By Application (Drug Discovery, Academics & Research), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 192 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球人類肝臟模型市場預計將從 2025 年的 6.5532 億美元大幅成長至 2031 年的 8.3784 億美元，複合年成長率為 4.18%。

該市場涵蓋了旨在模擬人類肝臟生理功能和運作的先進體外和體內系統，用於藥物研發和疾病研究，例如類器官、晶片肝臟平台和人源化動物模型。關鍵成長要素包括：迫切需要降低因藥物性肝損傷導致的高藥物研發失敗率；出於倫理考量減少動物實驗；以及日益嚴重的全球慢性肝病負擔，需要能夠準確預測疾病進展和治療結果的工具。例如，全球肝臟研究所預測，到2025年，全球近40%的人口將患有脂肪肝，顯示存在巨大的臨床需求。然而，檢驗和擴展這些複雜的微生理系統以實現廣泛的商業應用，其高成本和技術複雜性阻礙了這一強勁的成長勢頭。這些重大障礙會限制小規模研究機構的使用，延緩這些模型融入標準化監管流程，並阻礙價格敏感地區的市場擴張。

市場概覽
預測期 2027-2031
市場規模：2025年 6.5532億美元
市場規模：2031年 8.3784億美元
複合年成長率：2026-2031年 4.18%
成長最快的細分市場 2D模型
最大的市場 北美洲

市場促進因素

監管和倫理方面的轉變正在推動動物試驗替代方案的出現，從根本上改變全球人類肝臟模型市場，加速了高度相關的體外系統的應用。這一轉變得到了更新法規的積極支持，這些法規鼓勵製藥開發商使用微生理系統進行安全性測試，並擺脫對動物模型的壟斷性依賴。一個顯著的例子是美國FDA於2025年4月10日發布的藍圖（Holland & Knight於2025年4月報道）。該路線圖優先考慮“新的調查方法”，例如晶片器官平台，透過在臨床前工作流程中檢驗肝臟模型來加速市場成長。鑑於疾病負擔日益加重，這種檢驗至關重要。美國癌症協會估計，光是2025年，美國就將新增42,240例肝癌病例，凸顯了對精準預測工具的巨大需求。同時，3D生物列印和組織工程的快速發展正成為推動這一領域發展的第二個強大動力，直接應對可擴展性和生理精確性方面的挑戰。創新者們正在開發能夠簡化體外組織培養的整合解決方案，使這些先進工具能夠應用於更廣泛的研究領域。 2025年10月，CN Bio公司推出的PhysioMimix Core系統凸顯了這項進展。該系統是一體化的晶片器官系統，在單一器官和多器官配置中均展現出經驗證的性能。此類技術飛躍有效地降低了技術應用門檻，使製藥公司能夠將高通量肝臟模型無縫整合到其研發管線中。這種更便捷的獲取途徑確保了人類肝臟模型的更廣泛應用，有助於早期發現藥物引起的肝損傷，並最終減少代價高昂的後期臨床試驗的失敗。

市場挑戰

由於檢驗和擴展微生理系統需要大量的資本投入和技術複雜性，全球人類肝臟模型市場面臨嚴峻的挑戰。維護先進的「晶片上」肝臟平台和人源化模型的高昂營運成本，導致目前只有大型製藥企業才能使用這些平台，而規模小規模、預算有限的學術機構和受託研究機構則被排除在外。這種壟斷不僅限制了建立行業標準所需的大量數據的產生，還造成了監管整合延遲的惡性循環。根據 2025 年 IQ MPS Affiliate 報告顯示，一項由 26 家製藥公司參與的聯合舉措表明，建立完善的合格方案仍然是這些技術在工業層面常規應用的關鍵瓶頸。由於缺乏涵蓋整個行業的標準化檢驗，監管機構不願意完全接受這些模型的數據來取代傳統方法。這種技術瓶頸不僅減緩了整體應用速度，也阻礙了價格敏感地區的市場滲透。在這些地區，從成熟的動物模型過渡到昂貴的新系統，往往難以證明其成本效益。

市場趨勢

人工智慧 (AI) 與肝臟模型數據分析的融合正在顯著改變臨床前安全性評估，使人們能夠檢測到傳統檢測方法常常遺漏的毒性特徵。開發人員正在將機器學習與來自晶片肝臟平台的高維度數據相結合，以大幅提高藥物性肝損傷(DILI) 預測的準確性。一個值得關注的例子是 Cellarity 公司於 2025 年 11 月由 News-Medical.Net 報導的新型 AI 框架，該框架實現了 100% 的特異性和 88% 的靈敏度，在 DILI 預測方面顯著優於 20 個行業標準模型。這種協同方法使製藥公司能夠將複雜的生物資料集轉化為可操作的安全訊號，從而在研發早期降低候選藥物的風險。同時，利用誘導性多功能幹細胞細胞 (iPS 細胞) 開發的患者特異性模型的出現，直接解決了通用細胞株固有的限制。透過利用不同供體來源建構類器官，研究人員能夠更精確地模擬群體層面的變異性，並深入研究依賴獨特基因譜的特異性藥物反應。馬克斯普朗克學會於2025年12月重點介紹了這一關鍵趨勢，詳細闡述了科學家如何建構來自28位不同患者的功能性肝組織，從而準確捕捉個體代謝差異。此類創新對於確保新藥在進入臨床試驗前針對代表性的各類人類表現型進行全面測試至關重要，最終將有助於開發更安全、更有效的治療方法。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球人肝模型市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（2D模型、3D生物列印、肝臟類器官）
    • 按應用領域（藥物發現、學術研究/調查）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美人類肝臟模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲人類肝臟模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區人類肝臟模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲人類肝臟模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲人類肝臟模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球人類肝臟模型市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Emulate, Inc.
  • CN Bio Innovations Limited
  • TissUse GmbH
  • InSphero AG
  • Organovo Holdings, Inc.
  • Mimetas BV
  • HuREL Corporation
  • Nortis, Inc.
  • Kirkstall Limited
  • AlveoliX AG
  • REPROCELL Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17520

The Global Human Liver Model Market is projected for substantial growth, expanding from USD 655.32 Million in 2025 to USD 837.84 Million by 2031, at a CAGR of 4.18%. This market encompasses advanced in vitro and in vivo systems, including organoids, liver-on-a-chip platforms, and humanized animal models, all designed to replicate human liver physiology and function for drug development and disease research. Key growth drivers include the urgent need to reduce high pharmaceutical attrition rates caused by drug-induced liver injury, the ethical imperative to decrease animal testing, and the increasing global burden of chronic liver conditions, which necessitates accurate predictive tools for disease progression and therapeutic efficacy. For instance, the Global Liver Institute reported that fatty liver disease is expected to affect nearly 40% of the global population in 2025, highlighting a significant clinical demand. However, this robust growth trajectory is challenged by the high cost and technical complexity involved in validating and scaling these intricate microphysiological systems for broad commercial use. These formidable barriers restrict accessibility for smaller research institutions and slow the integration of these models into standardized regulatory protocols, potentially hindering market expansion in price-sensitive regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 655.32 Million
Market Size 2031USD 837.84 Million
CAGR 2026-20314.18%
Fastest Growing Segment2D Models
Largest MarketNorth America

Market Driver

Regulatory and ethical shifts advocating for alternatives to animal testing are fundamentally transforming the Global Human Liver Model Market, fostering the adoption of human-relevant in vitro systems. This transition is actively supported by legislative updates that encourage pharmaceutical developers to use microphysiological systems for safety testing, moving away from exclusive reliance on animal models. A notable example is the U.S. FDA's roadmap unveiled on April 10, 2025, as reported by Holland & Knight in April 2025, which prioritizes New Approach Methodologies such as organ-on-a-chip platforms, thereby accelerating market growth by validating liver models in preclinical workflows. This validation is critical given the growing disease burden, with the American Cancer Society estimating 42,240 new cases of liver cancer in the United States in 2025 alone, underscoring the demand for accurate predictive tools. Concurrently, rapid advancements in 3D bioprinting and tissue engineering serve as a second powerful catalyst, directly addressing issues of scalability and physiological accuracy. Innovators are developing integrated solutions that streamline in vitro tissue maintenance, making these sophisticated tools more accessible to a wider array of research segments. This progress was highlighted by CN Bio's launch of the PhysioMimix Core in October 2025, an all-in-one Organ-on-a-chip system offering validated performance across single and multi-organ configurations. Such technological leaps effectively lower the technical barrier to adoption, enabling pharmaceutical companies to seamlessly integrate high-throughput liver models into their pipelines. This enhanced accessibility ensures broader deployment of human liver models, facilitating earlier detection of drug-induced liver injury and ultimately reducing costly late-stage clinical failures.

Market Challenge

The Global Human Liver Model Market faces a formidable challenge due to the substantial financial investment and technical intricacy required for validating and scaling microphysiological systems. The high operational costs associated with maintaining sophisticated liver-on-a-chip platforms and humanized models primarily restrict their accessibility to large pharmaceutical enterprises, thereby excluding smaller academic institutions and contract research organizations operating with constrained budgets. This exclusivity not only limits the widespread generation of data necessary to establish industry-wide standards but also perpetuates a cycle of slow regulatory integration. According to the IQ MPS Affiliate in 2025, a collaborative initiative involving 26 pharmaceutical companies identified that establishing robust qualification packages remains a critical bottleneck for the routine industrial implementation of these technologies. Without standardized validation across this broad industrial base, regulatory bodies are hesitant to fully accept data from these models as a complete replacement for traditional methods. This technical bottleneck not only retards the overall rate of adoption but also stifles market penetration in price-sensitive regions, where the cost-benefit ratio of transitioning from established animal models to expensive, novel systems is often difficult to justify.

Market Trends

The convergence of artificial intelligence (AI) with liver model data analytics is significantly transforming preclinical safety assessment, enabling the detection of toxicity signatures that traditional assays often miss. Developers are increasingly integrating machine learning with high-dimensional data derived from liver-on-a-chip platforms to dramatically enhance the predictive accuracy for drug-induced liver injury (DILI). A notable example is Cellarity's novel AI framework, as reported by News-Medical.Net in November 2025, which demonstrated 88% sensitivity at 100% specificity, significantly outperforming twenty industry-standard models in DILI prediction. This synergistic approach empowers pharmaceutical companies to de-risk candidate drugs earlier in the development process by translating intricate biological datasets into actionable safety signals. Simultaneously, the emergence of patient-specific models developed using induced pluripotent stem cells (iPSCs) is directly addressing the inherent limitations of generic cell lines. By generating organoids from diverse donor backgrounds, researchers gain the capability to accurately replicate population-level variability and thoroughly study idiosyncratic drug reactions that are dependent on unique genetic profiles. This pivotal trend was underscored by the Max Planck Society in December 2025, which detailed how scientists engineered functional liver tissues derived from 28 distinct patients to precisely capture individual metabolic differences. Such innovations are crucial for ensuring that new drugs are comprehensively tested against a representative range of human phenotypes before their progression to clinical trials, leading to safer and more effective therapeutic development.

Key Market Players

  • Emulate, Inc.
  • CN Bio Innovations Limited
  • TissUse GmbH
  • InSphero AG
  • Organovo Holdings, Inc.
  • Mimetas B.V.
  • HuREL Corporation
  • Nortis, Inc.
  • Kirkstall Limited
  • AlveoliX AG
  • REPROCELL Inc.

Report Scope

In this report, the Global Human Liver Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Liver Model Market, By Product

  • 2D Models
  • 3D Bio Printing
  • Liver Organoids

Human Liver Model Market, By Application

  • Drug Discovery
  • Academics & Research

Human Liver Model Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Liver Model Market.

Available Customizations:

Global Human Liver Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Liver Model Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (2D Models, 3D Bio Printing, Liver Organoids)
    • 5.2.2. By Application (Drug Discovery, Academics & Research)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Human Liver Model Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Human Liver Model Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Human Liver Model Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Human Liver Model Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Human Liver Model Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Human Liver Model Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Human Liver Model Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Human Liver Model Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Human Liver Model Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Human Liver Model Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Human Liver Model Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Human Liver Model Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Human Liver Model Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Human Liver Model Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Human Liver Model Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Human Liver Model Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Human Liver Model Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Human Liver Model Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Human Liver Model Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Human Liver Model Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Human Liver Model Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Human Liver Model Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Human Liver Model Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Human Liver Model Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Human Liver Model Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Emulate, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. CN Bio Innovations Limited
  • 15.3. TissUse GmbH
  • 15.4. InSphero AG
  • 15.5. Organovo Holdings, Inc.
  • 15.6. Mimetas B.V.
  • 15.7. HuREL Corporation
  • 15.8. Nortis, Inc.
  • 15.9. Kirkstall Limited
  • 15.10. AlveoliX AG
  • 15.11. REPROCELL Inc.

16. Strategic Recommendations

17. About Us & Disclaimer